The MHRA position, summarised by Lynda Scammell (head of borderline products at the MHRA) and reported in The Guardian on 4 April 2026, is that products which are sold for human use or which carry medicinal claims fall inside the Human Medicines Regulations 2012, and that the MHRA is investigating UK clinics making such claims about unregulated peptide products
#anatomyandphysiology #nurse #nursingstudent #nursingstudenttips #notes #stealmynotes This is my quick go-to meds cheat sheet
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
However, in the areas of senile cataracts, cardiovascular disease, schizophrenia and autistic disorders, the results are inconclusive
It may help with weight management
Peptide therapy may be discussed for patients interested in recovery support, joint comfort, mobility, and post-exercise recovery